Canaccord Genuity Comments on Recent Journal Manuscripts Related to Thoratec Corporation's HeartMate II Device

In a report published Friday, Canaccord Genuity analyst Jason R. Mills reiterated a Buy rating and $45.00 price target on Thoratec Corporation THOR. In the report, Canaccord Genuity noted, “The New England Journal of Medicine (NEJM) and Journal of Heart & Lung Transplantation (JHLT) both published manuscripts online just before the Thanksgiving holiday that highlighted an increase in the frequency of device exchanges related to thrombus occurring with HeartMate II devices from Thoratec (THOR : NASDAQ : $42.12 | BUY).” Thoratec Corporation closed on Wednesday at $42.12.